SKTO SK3 Group Inc (CE)

LOS ANGELES, CA--(Marketwired - Jan 29, 2014) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens ("the Company") is pleased to announce that it has signed an exclusive distribution agreement for the Monarch Vaporizer from Monarch Vapes, a provider of portable personal vaporizers.

The Monarch vape pen is very easy to use by simply pushing the button and inhaling. A well-measured dose of vapor is dispensed automatically. The pen itself is easily re-energized with the included USB charger and has a particularly long battery life. Each cartridge contains upwards of 100 inhalations, and is then easily replaced with another pre-filled replacement cartridge, which will be available from PharmaJanes.com and other California medical marijuana dispensaries.

The Monarch Vaporizer provides the versatility of oil while allowing users to get the benefits of E-juice, a liquid that is commonly vaporized when using an e-cigarette. It is simple, sleek, discreet, and is manufactured with uncompromising quality. Monarch's approach allows users and patients to vaporize whenever and wherever without the judgment of others.

Monarch is in discussions to team up with other companies in order to introduce vaporizable products for the medical cannabis market.

In a 2006 study, researchers at Leiden University in the Netherlands compared vaporization to smoking pure THC and found that, "Our results show that a safe and effective cannabinoid delivery system seems to be available to patients. The final pulmonal uptake of THC is comparable to the smoking of cannabis, while avoiding the respiratory disadvantages of smoking."

Through this deal, Medical Greens is capitalizing on the wave of portable personal vape pens and the growth of vaporizing in general becoming an important accessory for a growing number of Americans.

"We are pleased to sign this exclusive distribution agreement with Monarch Vapes. The e-cigarette market is growing at a tremendous rate, and it is a product with direct applicability to the medical cannabis market," said Artemus Mayor, President of SK3 Group, Inc. "As the size of the e-cigarette market roughly doubled each year for the past several years, we expect similar growth in the medical cannabis vaporizer market and this is an opportunity to utilize the same technology to provide safer and more effective access for cannabis patients to medicate."

FDA Statement The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3 SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

investors@medicalgreens.com SK3 Investor Relations

SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From May 2024 to Jun 2024

SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Jun 2023 to Jun 2024